Health Canada has issued a recall for several cannabis oils and softgels due to the presence of unexpectedly high levels of THC and HHC, which are intoxicating substances and could be harmful to consumers.
The recall affects specific batches of Emprise CBN+CBD Softgels, NuLeaf Naturals Full Spectrum Hemp Multicannabinoid Oil and Oil Softgels, and Ultra Plus Multicannabinoid Oil and Softgels. These products were sold to customers by authorized retailers across British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Yukon between December 2022 and July 2024. Medical clients obtained these products through Rosebud Productions Inc., Open Fields Winnipeg, Open Fields Saskatchewan, and Médicibis in Quebec.
Health Canada and the recalling company, iNaturally Organic Inc., have both received reports of adverse reactions from consumers who used these products. As a precaution, Health Canada advises anyone who has purchased these products to stop using them immediately. Consumers are urged to either discard the products or return them to the place of purchase for a refund.
The recall highlights the importance of ensuring cannabis products meet safety standards. THC and HHC are known for their psychoactive effects, and consuming higher-than-expected levels can lead to significant health risks, including impaired cognitive and motor functions. This is particularly concerning for individuals who may be using these products for therapeutic purposes without expecting any psychoactive effects.
Emprise CBN+CBD Softgels, NuLeaf Naturals Full Spectrum Hemp Multicannabinoid Oil and Oil Softgels, and Ultra Plus Multicannabinoid Oil and Softgels are marketed as wellness products, often used for pain relief, anxiety reduction, and other health benefits. The unexpected presence of higher intoxicating compounds undermines their intended use and poses a safety risk.
Consumers who have experienced adverse reactions are encouraged to report them to Health Canada. This feedback is crucial for monitoring the safety of cannabis products and ensuring swift action can be taken when issues arise.
Health Canada continues to monitor the situation and will provide updates as necessary. The agency is committed to protecting public health and ensuring that all cannabis products on the market meet stringent safety and quality standards. This recall serves as a reminder for both consumers and manufacturers of the importance of transparency and rigorous testing in the cannabis industry.
In response to the recall, consumers are advised to check the labels of their cannabis products and verify if they are part of the affected batches. If so, they should follow the recall instructions promptly to avoid any potential health risks. For those seeking alternative products, consulting with authorized retailers and health professionals can guide safe and effective options.